Human T-lymphotropic virus 1 infectious disease
MONDO:0005801A viral infectious disease that results in increased proliferation of affected CD4 lymphocytes, has material basis in Human T-lymphotropic virus 1, which is transmitted by sexual contact, transmitted by contaminated needles used by intravenous-drug users, and transmitted by breast feeding. The person infected with HTLV-1 eventually develop an often rapidly fatal leukemia, while others will develop a debilitative myelopathy, uveitis, infectious dermatitis, or another inflammatory disorder.
Also known as: Human T-lymphotropic virus 1 caused disease or disorder, Human T-lymphotropic virus 1 disease or disorder, Human T-lymphotropic virus 1 infectious disease, human T-lymphotropic virus 1 infectious disease, HTLV-1, Human T lymphotropic virus type 1
37 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
Disease control Stopped earlyThis early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…
Phase 1/2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Promising combo for tough blood cancers halted early — only 4 patients enrolled
Disease control Stopped earlyThis study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early…
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC